Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zarnestra + Tamoxifen in Advanced Breast Cancer
NCT00210028Phase 2Terminated
- Sponsor
- Institut Claudius Regaud
- Start
- Aug 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in breast cancer, sponsored by Institut Claudius Regaud. Primary endpoint: Objective Response Rate. Started Aug 2003; status: terminated.
02
Drugs
tipifarnib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00210028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210028.